2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD, page-105

The next round of rewards

is when the news comes in that the PAA mpl tablet is having a therapeutically useful effect on the MND patients and FINALLY people start to wake up to the importance of this first fourth generation mTOR drug, and the leading contender for being the successor to rapamycin.


So far the news is that the drug has passed the first round of tests with no tolerability issues. It's early days yet but that's excellent news given the notorious experience of such issues with mTOR drugs, including with rapamycin itself. What a great start to the trial after the months of delay caused by patient issues that were not caused or planned by PAA in any way. Things are moving nicely now and the trial leaders and their teams are very experienced and competent people:

https://www.pharmaust.com/phamaust-webinar/

As for the dogs, the SD v PD ratio is academic if they are living markedly longer lives and ultimately, the whole point about PAA getting a dog deal is to be a stepping stone to human treatment.

Cheers